^
Association details:
| Biomarker: | TP53 wild-type |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | bortezomib (Proteasome inhibitor) + alrizomadlin (APG-115) (MDM2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5439 - MDM2 inhibitor alrizomadlin (APG-115) stabilizes p53 and synergizes with proteasome inhibitors in multiple myeloma
Published date:
03/09/2022
Excerpt:
In cell-based antiproliferation studies, alrizomadlin demonstrated selective activity against WT TP53 MM cell lines, including MOLP-8, H929, and MM1S...In vivo studies showed that coadministration of alrizomadlin with proteasome inhibitor bortezomib or carfilzomib enhanced tumor regression (vs. single agents) in H929 xenograft models...the combination of MDM2 inhibitor APG-115 and proteasome inhibitors have synergistic antitumor effects on MM tumors harboring WT TP53.
